Selection of DNA aptamers for sensing drugs treating eye disease: atropine and timolol maleate

3Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Effective monitoring of ocular drugs is crucial for personalized medicine and improving drug delivery efficacy. However, traditional methods face difficulties in detecting low drug concentrations in small volumes of ocular fluid, such as that found on the ocular surface. In this study, we used capture-SELEX to select aptamers for two commonly used ocular drugs, timolol maleate and atropine. We identified TMJ-1 and AT-1 aptamers with binding affinities of 3.4 μM timolol maleate and 10 μM atropine, respectively. Our label-free TMJ-1 biosensor using thioflavin T staining achieved a limit of detection (LOD) of 0.3 μM for timolol maleate. The AT-1 biosensor showed an LOD of 1 μM for atropine, and exhibited a 10-fold higher sensitivity compared to UV-visible spectroscopy. Future research in this area holds promise in enhancing drug delivery monitoring and improving the treatment of ocular diseases.

Cite

CITATION STYLE

APA

Wong, K. Y., Liu, Y., Phan, C. M., Jones, L., Wong, M. S., & Liu, J. (2024). Selection of DNA aptamers for sensing drugs treating eye disease: atropine and timolol maleate. Sensors and Diagnostics, 3(10), 1679–1688. https://doi.org/10.1039/d4sd00223g

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free